ScholarIQanswers from OpenAlex

Abstract 5183: Correlation of cell adhesion molecules expression and prognosis in clinically localized prostate cancer

PaperCitations, authors & open-access status

Abstract 5183: Correlation of cell adhesion molecules expression and prognosis in clinically localized prostate cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Abstract 5183: Correlation of cell adhesion molecules expression and prognosis in clinically localized prostate cancer have?

ScholarIQcitation count

Abstract 5183: Correlation of cell adhesion molecules expression and prognosis in clinically localized prostate cancer has 0 citations in the OpenAlex counts ScholarIQ stores.

When was Abstract 5183: Correlation of cell adhesion molecules expression and prognosis in clinically localized prostate cancer published?

ScholarIQyear

Abstract 5183: Correlation of cell adhesion molecules expression and prognosis in clinically localized prostate cancer has 2010 year in the ScholarIQ index.

What is the open-access status of Abstract 5183: Correlation of cell adhesion molecules expression and prognosis in clinically localized prostate cancer?

ScholarIQoa status

Abstract 5183: Correlation of cell adhesion molecules expression and prognosis in clinically localized prostate cancer has closed oa status in the ScholarIQ index.

What is the DOI of Abstract 5183: Correlation of cell adhesion molecules expression and prognosis in clinically localized prostate cancer?

ScholarIQdoi

The DOI for Abstract 5183: Correlation of cell adhesion molecules expression and prognosis in clinically localized prostate cancer is on the source record.

What is the OpenAlex record for Abstract 5183: Correlation of cell adhesion molecules expression and prognosis in clinically localized prostate cancer?

ScholarIQopenalex

The OpenAlex for Abstract 5183: Correlation of cell adhesion molecules expression and prognosis in clinically localized prostate cancer is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial